CNS & Neurological Disorders-Drug Targets

Papers
(The H4-Index of CNS & Neurological Disorders-Drug Targets is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Neuroprotection of Rotenone-Induced Parkinsonism by Ursolic Acid in PD Mouse Model58
Role of Calcium Homeostasis in Ischemic Stroke: A Review46
Benzodiazepines and Sleep Architecture: A Systematic Review44
Inflammation and Mitochondrial Dysfunction in Autism Spectrum Disorder43
Neurodegenerative Diseases and Flavonoids: Special Reference to Kaempferol35
Autoimmune Encephalitis: Current Knowledge on Subtypes, Disease Mechanisms and Treatment31
Role of Brain-Gut-Microbiota Axis in Depression: Emerging Therapeutic Avenues27
Role of Vitamins in Neurodegenerative Diseases: A Review26
Speech as a Biomarker for Depression24
Arachidonic Acid Derivatives and Neuroinflammation23
Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives23
Valproic Acid and Propionic Acid Modulated Mechanical Pathways Associated with Autism Spectrum Disorder at Prenatal and Neonatal Exposure19
The MMP-2/TIMP-2 System in Alzheimer Disease19
ATP-sensitive Potassium Channel Subunits in Neuroinflammation: Novel Drug Targets in Neurodegenerative Disorders18
Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases18
Current Strategies and Novel Drug Approaches for Alzheimer Disease18
Modeling Parkinson’s Disease in Zebrafish18
The Effects and Regulatory Mechanism of Flavonoids from Stems and Leaves of Scutellaria baicalensis Georgi in Promoting Neurogenesis and Improving Memory Impairment Mediated by the BDNF-ERK-CREB Signa17
Persons with Co-Existing Neurological Disorders: Risk Analysis, Considerations and Management in COVID-19 Pandemic17
Melatonin and Sleep Disturbances in Alzheimer’s Disease17
Pharmacological Treatment of Diabetic Peripheral Neuropathy: An Update17
0.21465611457825